"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
| Descriptor ID |
D002945
|
| MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
| Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 1 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 3 | 3 |
| 2002 | 1 | 2 | 3 |
| 2003 | 4 | 2 | 6 |
| 2004 | 4 | 3 | 7 |
| 2005 | 1 | 3 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 5 | 6 |
| 2008 | 2 | 5 | 7 |
| 2009 | 0 | 4 | 4 |
| 2010 | 1 | 4 | 5 |
| 2011 | 2 | 5 | 7 |
| 2012 | 1 | 3 | 4 |
| 2013 | 4 | 4 | 8 |
| 2014 | 3 | 5 | 8 |
| 2015 | 5 | 8 | 13 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 2 | 4 |
| 2018 | 6 | 1 | 7 |
| 2019 | 8 | 5 | 13 |
| 2020 | 0 | 6 | 6 |
| 2021 | 1 | 5 | 6 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 9 | 9 |
| 2024 | 4 | 6 | 10 |
| 2025 | 7 | 3 | 10 |
| 2026 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis. ESMO Open. 2026 Jul; 11(7):108248.
-
Targeted suppression of SPP1 inhibits tumor invasion and metastasis in NRF2 hyperactivated cisplatin resistant HNSCC. J Transl Med. 2026 May 22; 24(1).
-
Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2026 09 01; 126(1):118-133.
-
Investigating the oncogenic role of aberrant EZH2 in hepatoblastoma. Sci Rep. 2026 Feb 06; 16(1).
-
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030). J Natl Cancer Inst. 2026 Jan 01; 118(1):141-149.
-
Naringenin-functionalized polyester nanoparticles improve oral urolithin A delivery and protect against cisplatin-induced kidney injury via heme oxygenase-1 activation and mitochondrial quality control. J Pharmacol Exp Ther. 2026 Feb; 393(2):103794.
-
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. Br J Cancer. 2025 Dec; 133(12):1802-1814.
-
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy. BJU Int. 2026 Jan; 137(1):181-188.
-
Dual-function polyester nanoparticles for amplified anti-inflammatory effects. Sci Adv. 2025 Aug 08; 11(32):eadw1358.
-
Integrated network pharmacology and molecular docking combined with metabolomics to identify the pharmacological mechanisms of Jiedu Huoxue decoction against cisplatin-induced acute kidney injury. J Ethnopharmacol. 2025 Jul 24; 351:120088.